The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer.
Ravi Amrit Madan
No relevant relationships to disclose
Nishith K. Singh
No relevant relationships to disclose
Ann Wild Gramza
No relevant relationships to disclose
Antonio Tito Fojo
No relevant relationships to disclose
Christopher Ryan Heery
No relevant relationships to disclose
Joseph W. Kim
No relevant relationships to disclose
Sheri McMahon
No relevant relationships to disclose
Myrna Rauckhorst
No relevant relationships to disclose
Thomas H King
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
Research Funding - GlobeImmune
David Apelian
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
Jeffrey Schlom
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose